BioVie to Present Protocol Design for Upcoming Phase 2 Trial of Bezisterim in Patients with Early Parkinson’s Disease at 2024 ATMRD Congress

June 20, 2024

https://www.globenewswire.com/news-release/2024/06/20/2901612/0/en/BioVie-to-Present-Protocol-Design-for-Upcoming-Phase-2-Trial-of-Bezisterim-in-Patients-with-Early-Parkinson-s-Disease-at-2024-ATMRD-Congress.html

CARSON CITY, Nev., June 20, 2024 (GLOBE NEWSWIRE) — BioVie Inc., (NASDAQ:BIVI) (“BioVie” or the “Company”) a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease, today announced two poster presentations at the Advanced Therapeutics in Movement and Related Disorders Congress® (ATMRD Congress) being held June 21-25, 2024 in Washington, D.C.

Read more at globenewswire.com

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.